Imugene presents azer-cel data at ASCO as trial expands into new cohort

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has presented new Phase 1b data for its azer-cel cell therapy at the 2026 American Society of Clinical Oncology...